Abstracts tagged "Myopathies"

Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0443 • ACR Convergence 2021
Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
Priyal Chadha¹, Sonali Narain², Preeya Nandkumar³, Cristine Sison⁴, Elena Schiopu⁵, Todd Levine⁶, James Tsang⁷ and Galina Marder⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Department of Medicine, Northwell, Great Neck, NY, ⁴Biostatistics Unit , Department of Molecular Medicine, Feinstein Institutes for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵University of Michigan, Ann Arbor, MI, ⁶Phoenix Neurological Associates, Phoenix, AZ, ⁷Center for Research Informatics & Innovation (CRII), Feinstein Institute for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Treatment of Idiopathic Inflammatory Myositis (IIM) includes steroids and immunosuppressive agents. Targeting IL6, IL1, TNF for treatment of IIM has not been successful, and…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 1062 • ACR Convergence 2020
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
Burak Elkiran¹, Mahroo Tajalli², Terrence M. Vance³, Abrar A. Qureshi⁴ and Anthony M. Reginato⁵, ¹Department of Medicine, Division of Rheumatology; Warren Alpert Medical School of Brown University, BOSTON, ²Department of Dermatology, Warren Alpert Medical School of Brown University, PROVIDENCE, ³Department of Epidemiology, Warren Alpert Medical School of Brown University, PROVIDENCE, ⁴Department of Dermatology, Warren Alpert Medical School of Brown University, BOSTON, ⁵Department of Medicine, Division of Rheumatology, Warren Alpert Medical School of Brown University, Boston, MA
Background/Purpose: Dermatomyositis (DM) can be categorized into two major subtypes: clinically amyopathic dermatomyositis (CADM) and classic dermatomyositis (CDM). In this study, we aimed to identify characteristics…
Abstract Number: 1064 • ACR Convergence 2020
Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis
Caroline Vo¹, Océane Landon-Cardinal², Alexandra Albert³, Alain Meyer⁴, Valérie Leclair⁵, Josiane Bourré-Tessier², Sabrina Hoa², Eric Rich¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Maude Bouchard-Marmen⁷, Martial Koenig⁸, Geneviève Gyger⁵, Ira N. Targoff⁹, Marie Hudson⁵, Minoru Satoh¹⁰, Marvin Fritzler¹¹, Yves Troyanov¹² and Jean-Luc Senécal², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁶Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, ⁷Division of Rheumatology, Centre Hospitalier de l’Université Laval, Department of Medicine, Université Laval, Québec, QC, Canada, ⁸Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada
Background/Purpose: The survival of motor neuron (SMN)/gemin proteins are components of a multifunctional protein complex that plays an essential role in RNA metabolism. SMN is…
Abstract Number: 1069 • ACR Convergence 2020
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Martial Koenig⁴, Alain Meyer⁵, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Isabelle Ferdinand⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Benjamin Ellezam¹¹, Jean-Luc Senécal¹, Marie Hudson² and Geneviève Gyger², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁶Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc) and characterized by prominent vasculopathic features on ultrastructural…
Abstract Number: 1070 • ACR Convergence 2020
Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Alain Meyer⁴, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Valérie Nadon⁵, Julie Drouin⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Jean-Luc Senécal¹, Marie Hudson² and Benjamin Ellezam¹¹, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Hôpital Notre-Dame, Montreal, Québec, Canada, Montréal, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier régional de Trois-Rivières, Trois-Rivières, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis (AIM) associated with features of systemic sclerosis (SSc). Muscle biopsy studies are sparse and have…
Abstract Number: 1072 • ACR Convergence 2020
Sexual Health Impairment in 62 Female Patients with Idiopathic Inflammatory Myopathies
Barbora Hermankova¹, Maja Spiritovic², Sabina Oreska³, Hana Storkanova⁴, Hana Smucrova⁵, Martin Komarc⁶, Martin Klein⁴, Karel Pavelka⁷, Ladislav Šenolt⁷, Jiří Vencovský⁷, Heřman Mann⁴ and Michal Tomcik⁴, ¹Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Hlavni mesto Praha, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare diseases characterized by chronic muscle inflammation and multiple organ involvement. These serious clinical manifestations…
Abstract Number: 1079 • ACR Convergence 2020
Sex Differences in Antibody Profile, Phenotype, and Treatment Response in a Racially Diverse Population with Idiopathic Inflammatory Myopathies
Ana Valle¹, Jammie Law², Katherine Mullins³ and Shereen Mahmood⁴, ¹Albert Einstein College of Medicine, New York, NY, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: It is established that autoimmune diseases are more common in females than males. Large scale idiopathic inflammatory myopathy (IIM) registries have shown a similar…
Abstract Number: 1080 • ACR Convergence 2020
Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America
Antonia Maria Valenzuela Vergara¹, Magdalena Torres¹ and Alejandro Deves¹, ¹Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…
Abstract Number: 1083 • ACR Convergence 2020
Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
Sabina Oreska¹, Hana Storkanova², Maja Spiritovic³, Barbora Hermankova⁴, Michal Vrablik⁵, Karel Pavelka⁶, Ladislav Šenolt⁶, Heřman Mann², Jiří Vencovský⁶ and Michal Tomcik⁷, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 1086 • ACR Convergence 2020
The Diagnostic Value and Clinical Significance of Myositis-Specific Antibodies in Patients Suspected to Have Autoimmune Myopathies and/or Autoimmune Rheumatic Diseases
Sarah El Chami¹, Christopher Williams¹, Ghaith Noaiseh¹, Amrita Bath¹ and Duaa Jabari¹, ¹The University of Kansas Health System, Kansas city, KS
Background/Purpose: Myositis-specific antibodies (MSA) are thought to be highly specific in patients with idiopathic inflammatory myopathies.[1] However, in clinical practice these antibodies are frequently found…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].